Steve Thorne
Company: Kalivir Immunotherapuetics
Job title: Chief Scientific Officer
Seminars:
Expression of a TGF-β Inhibitor from an Oncolytic Vaccinia Virus 2:30 pm
• The VET platform developed by Kalivir allows systemic delivery of oncolytic virus therapies to tumors • Oncolytic viruses express transgenes to high levels locally within a tumor, so reducing the safety concerns of systemic delivery of recombinant proteins or antibodies • Oncolytic viruses expressing a TGF-β mini-monomer to block TGF-β receptor activation display enhanced…Read more
day: Day One